Literature DB >> 1330598

Pantoprazole: a novel H+/K(+)-ATPase inhibitor with an improved pH stability.

W Beil1, U Staar, K F Sewing.   

Abstract

The action of the H+/K(+)-ATPase inhibitors pantoprazole and omeprazole was compared in different in vitro test systems. In gastric membrane vesicles under conditions shown to result in acidification of the vesicle interior, pantoprazole and omeprazole inhibited H+/K(+)-ATPase activity with IC50 values of 6.8 and 2.4 microM, respectively. When intravesicular acidification was reduced by inclusion of imidazole (5 mM), a membrane permeable weak base, the inhibitory action of omeprazole was partially lost (IC50 30 microM) and that of pantoprazole almost completely lost. After incubation for 40 min with pumping membrane vesicles, a half-maximal reduction in intravesicular H+ concentration occurred at pantoprazole and omeprazole concentrations of 1.1 and 0.6 microM, respectively. Again, when the intravesicular H+ concentration was reduced by inclusion of imidazole (2.5 mM), pantoprazole (20 and 60 microM) did not reduce the remaining intravesicular proton concentration, whereas omeprazole (10 and 30 microM) did. Both drugs inhibited, with similar potency, papain activity at pH 3.0 and inactivated the enzyme in a similar time-dependent manner; at pH 5.0 omeprazole (IC50 17 microM) was more potent than pantoprazole (IC50 37 microM) and enzyme inhibition was faster than with pantoprazole. These results indicate that pantoprazole is a potent inhibitor of H+/K(+)-ATPase under highly acidic conditions and that it is more stable than omeprazole at a slightly acidic pH such as pH 5.0.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1330598     DOI: 10.1016/0014-2999(92)90178-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders.

Authors:  A Fitton; L Wiseman
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 2.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

3.  Comparison of the effect of a single dose of erythromycin with pantoprazole on gastric content volume and acidity in elective general surgery patients.

Authors:  Nidhi Bhatia; Sanjeev Palta; Kanika Arora
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2011-04

Review 4.  Proton pump inhibitory therapy: then and now.

Authors:  W Schepp
Journal:  Yale J Biol Med       Date:  1996 Mar-Apr

5.  Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole-In Vitro and In Vivo Investigations.

Authors:  Nibal Betari; Kristoffer Sahlholm; Xavier Morató; Héctor Godoy-Marín; Olga Jáuregui; Knut Teigen; Francisco Ciruela; Jan Haavik
Journal:  Front Pharmacol       Date:  2020-11-26       Impact factor: 5.810

Review 6.  Transforming growth factor-β in tumour development.

Authors:  Charles B Trelford; Lina Dagnino; Gianni M Di Guglielmo
Journal:  Front Mol Biosci       Date:  2022-10-04

7.  Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans.

Authors:  M Katashima; K Yamamoto; Y Tokuma; T Hata; Y Sawada; T Iga
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jan-Mar       Impact factor: 2.569

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.